PTH-Based Medicines Reshape Bone Health Treatment for Osteoporosis and Beyond

Parathyroid hormone is the master regulator of calcium and phosphate homeostasis, acting on bone and kidney to keep serum calcium in a tightly controlled range. Beyond mineral metabolism, PTH directly stimulates osteoblasts and osteocytes and, through the RANK/RANKL system, indirectly activates osteoclasts. The net skeletal outcome—bone gain or loss—depends critically on the pattern of PTH exposure: intermittent pulses favor anabolic bone formation, while sustained elevation (as in primary hyperparathyroidism or continuous infusion) promotes net bone resorption.

This 2025 review from Bonnet, Aboishava, and Mannstadt (Endocrine Unit, MGH/Harvard) synthesizes the current landscape of PTH-based pharmaceuticals. Teriparatide (PTH 1-34) and the PTHrP analog abaloparatide, both administered once daily by subcutaneous injection, are the two approved anabolic agents for osteoporosis. Both stimulate significant increases in bone mineral density and reduce fracture risk, with abaloparatide showing a more selective anabolic-to-catabolic ratio due to differential PTH1R signaling bias. Clinical guidelines generally reserve these agents for patients at high or very high fracture risk, often followed by antiresorptive therapy to consolidate gains.

For hypoparathyroidism—a condition of chronic PTH deficiency causing hypocalcemia and hypercalciuria—long-acting PTH analogs represent a paradigm shift. TransCon PTH (palopegteriparatide), a prodrug that releases teriparatide slowly to approximate physiological PTH levels across 24 hours, received FDA approval in 2024. Clinical trials demonstrated normalization of serum calcium while reducing urinary calcium excretion and lowering reliance on large oral calcium and active vitamin D supplements, which are associated with renal and soft-tissue complications in conventional management.

Emerging therapies include next-generation long-acting constructs, novel PTH fragments with receptor-biased signaling profiles, and small-molecule agonists of PTH1R (a class B GPCR). Small molecules could offer oral bioavailability, a major convenience advantage over injectable peptides. Research is also exploring PTH analogs for fracture healing acceleration and oral/dental bone repair—applications where PTH's direct osteoanabolic capacity could address unmet clinical needs.

The review also highlights mechanistic advances: cryo-EM structures of PTH1R have clarified how PTH and analogs engage the receptor's extracellular and transmembrane domains, enabling rational design of biased agonists that preferentially activate cAMP/PKA pathways (anabolic) over β-arrestin recruitment (linked to receptor downregulation and potentially catabolic signaling). These structural insights are guiding the development of next-generation molecules with improved efficacy, duration of action, and tissue selectivity.